Who are Course B1 +Vin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HDS vs ProMECE/CytaBOM, PAx5/PCMx5, Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan, Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Modified HIT-SKK Cycle B4-5, PACx14.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/course-b1-vin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Course B1 +Vin — Competitive Intelligence Brief

Course B1 +Vin (Course B1 +Vin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Multi-agent chemotherapy regimen. Area: Oncology.

phase 3 Multi-agent chemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Course B1 +Vin (Course B1 +Vin) — Children's Cancer Group, China. Course B1 + Vin is a chemotherapy combination regimen that uses vincristine (Vin) alongside other agents in Course B1 to disrupt microtubule formation and induce apoptosis in cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Course B1 +Vin TARGET	Course B1 +Vin	Children's Cancer Group, China	phase 3	Multi-agent chemotherapy regimen
HDS vs ProMECE/CytaBOM	HDS vs ProMECE/CytaBOM	Gruppo Italiano Studio Linfomi	phase 3	Multi-agent chemotherapy regimen
PAx5/PCMx5	PAx5/PCMx5	SWOG Cancer Research Network	phase 3	Multi-agent chemotherapy regimen
Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan	Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan	Dutch Childhood Oncology Group	phase 3	Multi-agent chemotherapy regimen; alkylating agents, antimetabolite, topoisomerase II inhibitor
Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone	Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone	St. Jude Children's Research Hospital	phase 3	Multi-agent chemotherapy regimen
Modified HIT-SKK Cycle B4-5	Modified HIT-SKK Cycle B4-5	Nationwide Children's Hospital	phase 3	Multi-agent chemotherapy regimen
PACx14	PACx14	SWOG Cancer Research Network	phase 3	Multi-agent chemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Multi-agent chemotherapy regimen class)

St. Jude Children's Research Hospital · 3 drugs in this class
Nationwide Children's Hospital · 2 drugs in this class
SWOG Cancer Research Network · 2 drugs in this class
Children's Cancer Group, China · 1 drug in this class
Gruppo Italiano Studio Linfomi · 1 drug in this class
Polish Adult Leukemia Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Course B1 +Vin — Competitive Intelligence Brief. https://druglandscape.com/ci/course-b1-vin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab